Indications, techniques, and safety of cryotherapy and cryobiopsy via flexible bronchoscopy in pediatric patients Authors: Alex J Katz, Haley Haskett, Kubra M Bozkanat, Aoife Corcoran, Lauren M C Grant, Antoinette Wannes Daou, Sin Tran, Esra Caylan, Alfin Vicencio, Dan T Benscoter, Cherie A Torres-Silva, Sara M Zak, Gregory Burg, Lisa R Young, Pelton Phinizy, Shailendra Das, Richard Paul Boesch, Erik B Hysinger, Joseph Piccione Published: 2026 ABSTRACT AbstractRationaleCryotherapy and its diagnostic analogue, cryobiopsy, are emerging techniques via bronchoscopy with a wide range of clinical applications. While the use of cryotherapy and cryobiopsy has been established in adult pulmonary medicine, pediatric data describing the indications, procedural specifics, outcomes, and complications are limited.ObjectiveTo describe the indications, procedural specifics, outcomes, and complications of cryotherapy and cryobiopsy use in pediatric bronchoscopy.MethodsA multicenter retrospective observational study was conducted at 5 pediatric hospitals in the United States. Patients aged 0 to 21 years who underwent cryotherapy or cryobiopsy via bronchoscopy between January 2017 and January 2025 were included.ResultsA total of 317 cryotherapy and cryobiopsy procedures were performed in 187 patients (median age 10 [3, 15] years; 44% female). The most common indication was cryoextraction (50%), followed by cryorecanalization (38%) and cryobiopsy (17%). The 1.1-mm cryoprobe was used in 57% of cases. Cryoextraction was at least partially successful in 95% of procedures, with the most common use being removal of blood clots (57%). Cryorecanalization was at least partially successful in 93% of procedures. The use of cryobiopsy has grown the most over the past 2 years. Cryobiopsy yielded successful histopathologic evaluation in 96% of biopsy specimens with 73% diagnostic yield. Bleeding was the most common complication of cryotherapy, occurring in 35% of cases, with 96% being grade 1 or 2. No pneumothorax was observed. Other complications were rare.ConclusionsCryotherapy and cryobiopsy via bronchoscopy in pediatrics have been increasingly used, demonstrating high success and a favorable safety profile. The introduction of the 1.1-mm cryoprobe has facilitated its broader application to pediatrics. Bleeding was the most common complication but was generally mild in the context of the selected cases at specialized centers.Keywords: child, biopsy, hospitals, pediatric, pulmonary medicine Introduction Cryotherapy and cryobiopsy refer to the therapeutic and diagnostic applications of cold temperatures. This technology has been employed medically to destroy and extract tissue in the airway since the 1960s.1 The recent development of small flexible cryotherapy probes has facilitated endoscopic applications. With the introduction of a 1.1-mm catheter in recent years, the technology can now be utilized through the smallest working channels in pediatric bronchoscopy.1 Cryotherapy and cryobiopsy operate on the Joule-Thomson effect of thermodynamics, which describes the change in temperature of a real gas (cryogen) when it is released through a nozzle into a lower-pressure environment. Common gases used include nitrous oxide, nitrogen, and carbon dioxide, which can achieve temperatures as low as −50 °C. Through small cryoprobes in flexible bronchoscopy, 3 primary applications have been identified: biopsy (cryobiopsy), restoring airway patency (cryorecanalization), and foreign body removal (cryoextraction).2,3 While this cold technology has been used extensively in adult interventional pulmonology, there are limited pediatric data. Over the past decade, cryotherapy and cryobiopsy via bronchoscopy have successfully diagnosed pediatric interstitial lung disease; removed foreign bodies, including plastic bronchitis; enhanced mucus clearance; and treated airway stenosis.4-11 More recently, it has been reported for transbronchial cryobiopsies of pediatric nodal lesions.12 It has been safely done for pediatric patients on extracorporeal membrane oxygenation (ECMO), even during the neonatal period.7,13,14 The largest study on cryotherapy and cryobiopsy in the pediatric airway, with 69 procedures, has demonstrated favorable success and safety for all 3 applications.15 Despite the studies detailing the variety of uses in pediatrics, little is known about the overall safety and efficacy on a large scale across multiple institutions. When examining recent adult literature using large (2.4-mm) cryoprobes, bleeding is one of the most common complications, with moderate bleeding occurring in 8% to 12% of patients, depending on the indication and application.16,17 Pneumothorax is also reported in similar cohorts of patients, ranging from 8% to 10%.16,18 The smaller 1.1-mm cryoprobe has likely reduced some of this risk, with the FROSTBITE trial showing mild (grade 1) bleeding in 50% of adult patients but moderate (grade 2) bleeding in only 4%.19,20 These newer data are promising for the safety of cryotherapy and cryobiopsy, although complications from their use are likely multifactorial and include underlying risk factors and procedural techniques. As the use of this technology grows in pediatrics, it will be imperative for bronchoscopists to understand the risks to this specific population. Therefore, we conducted a multicenter retrospective review of pediatric cryotherapy and cryobiopsy via bronchoscopy across 5 centers in the United States to evaluate the indications, procedural specifics, outcomes, and complications. Methods A retrospective observational study was conducted on pediatric patients aged 0 through 21 years at 5 pediatric hospitals across the United States who underwent cryotherapy or cryobiopsy via flexible bronchoscopy between January 2017 and January 2025. The study was deemed exempt from institutional review board oversight (IRB 23-021379). The electronic medical record was abstracted for demographic characteristics, procedural details (including any artificial airway), the bronchoscope type, cryoprobe and cryogen used, indications for use, outcomes, and complications encountered. Descriptive statistics were used for continuous and categorical variables. Sample cases were reviewed across institutions to enhance consistency in reporting. Bleeding was reported according to standardized definitions provided by the Nashville Working Group (Table 1).20 Success of the cryorecanalization and cryoextraction procedures was recorded as “yes,” “no,” or “partial” at the discretion of the bronchoscopist based on review of the medical record. Diagnostic yield was reported based on whether the biopsy led to a diagnosis. Table 1Standardized definitions of bleeding.aGradeDefinition 1 Suctioning of blood for less than 1 minute with no clinical consequence 2 Longer suctioning of blood, wedging of the bronchoscope, and/or instillation of cold saline or vasoactive substance 3 Bronchial blocker, selective intubation, and/or interruption of the procedure; results in a short-term clinical status change 4 Results in persistent intubation, new admission to an intensive care unit, transfusion, or other resuscitationaAdapted from Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18 Standardized definitions of bleeding.a Adapted from Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18 Results Demographics A total of 317 cryotherapy and cryobiopsy procedures via flexible bronchoscopy were identified in 187 patients across the 5 participating centers, ranging from 15 to 121 procedures per institution. The median age was 10 years, and the youngest patient was 2 days old. Forty-four percent of the patients were female. The median weight and height were 30 kg and 131 cm, respectively. Fifty-eight percent of the patients were inpatient prior to undergoing their bronchoscopy (Table 2). Table 2Demographics.aCharacteristicValue Number of patients 187 Number of procedures 317 Age,b y 10 [3, 14] Sex Female 83 (44) Male 104 (56) Race and ethnicity American Indian/Alaska Native 2 (1) Asian 8 (4) Black or African American 34 (18) Hispanic or Latino 22 (12) Native Hawaiian or Pacific Islander 0 (0) White 113 (60) More than 1 race 5 (3) Unknown/not reported 5 (3) Weight,b kg 30 [14, 58] Height,b cm 131 [96, 162] Inpatient prior to procedure 185 (58)aValues are reported as number (%) unless otherwise indicated.bReported median [interquartile range] based on date of procedure. Demographics.a Values are reported as number (%) unless otherwise indicated. Reported median [interquartile range] based on date of procedure. Procedure setup and indications The majority (66%) of procedures were done in an operating room or procedure room, with the remaining conducted at the bedside. Most procedures were carried out through an endotracheal tube (69%), followed by a laryngeal mask airway (14%) and a tracheostomy tube (9%). The remaining procedures were done through the nose or mouth (10%), with 5 using suspension laryngoscopy to improve airway accessibility (Table 3). Seven cases used multiple types of airways. The most frequently employed bronchoscope had an outer diameter of 4.2 ± 0.2 mm with a 2-mm working channel, with the 1.1-mm cryoprobe (57%) being most commonly used (Table 4). There were 34 (11%) procedures performed while patients were on ECMO and 3 (1%) while patients were supported by durable mechanical circulatory support, such as an Impella or ventricular assist device. Table 3Location and airway.CharacteristicNo. (%) Location Operating/procedure room 210 (66) Bedside 107 (34) Airway Nasal 23 (7) Oral 9 (3) Endotracheal tube (mm) 218 (69) 3.5 34 (16) 4.0 8 (4) 4.5 16 (7) 5.0 27 (12) 5.5 18 (8) 6.0 19 (9) 6.5 17 (8) 7.0 25 (11) 7.5 12 (6) 8.0 37 (17) Not reported 5 (2) Tracheostomy tube (mm) 29 (9) 3.5 9 (31) 4.0 3 (10) 4.5 5 (17) 5.0 6 (21) 5.5 2 (7) 6.0 5 (17) 6.5 0 (0) 7.0 1 (3) Not reported 2 (7) Laryngeal mask airway (size) 44 (14) 2 11 (25) 2.5 10 (23) 3 8 (18) 4 6 (14) Not reported 9 (20) Location and airway. Table 4Equipment.CharacteristicNo. (%) Bronchoscope size (mm)a 3 94 (30) 3.7 30 (9) 4 153 (45) 5.2 6 (1) 5.8 13 (4) 6.2 14 (4) 6.9 6 (2) Working channel size (mm) 1.2 91 (29) 1.7 20 (6) 2.0 160 (50) 2.2 14 (4) 2.8 30 (9) Cryoprobe (mm) 1.1 180 (57) 1.7 64 (20) 1.9 13 (4) 2.4 3 (1) Not reported 66 (21) Cryogen Carbon dioxide (CO2) 267 (84) Nitrous oxide (N2O) 30 (9) Not reported 20 (6)aIncludes ±2 mm to account for variation in reported scope diameter. Equipment. Includes ±2 mm to account for variation in reported scope diameter. The most common indication was cryoextraction (n = 159, 50% of all procedures), which encompassed blood clots (57%), casts (23%), mucus plugs (16%), and foreign bodies (11%) (Table 5). There were 55 (17%) cryobiopsies (Table 6) and 119 (38%) cryorecanalization procedures (Table 7). Supplementary navigational tools were used in 28 (9%) of procedures, which included endobronchial ultrasound in 21 cases, fluoroscopy in 11 cases, and computed tomography navigation in 9. All lymph node biopsies were done with linear endobronchial ultrasound, and all transbronchial lung biopsies were aided with navigation tools, including one with robotic bronchoscopy. Seventeen procedures included multiple indications (eg, cryoextraction and cryobiopsy). Notably, the use of cryotherapy and cryobiopsy increased over the past 2 years, with the share of cryobiopsy increasing the most (Figure 1). Table 5Cryoextraction.IndicationTotal, No. (%)Cryoextraction ­success, No. (%)YesPartialNo Foreign body 18 (11)3 (17)7 (39)8 (44) Mucus plugs 25 (16)14 (56)11 (44)0 (0) Blood clot 90 (57)51 (57)38 (42)1 (1) Casts (plastic bronchitis) 36 (23)23 (64)13 (36)0 (0) Total 159a87 (55)64 (40)9 (6)aTen procedures have multiple extraction indications. Cryoextraction. Ten procedures have multiple extraction indications. Table 6Cryobiopsy.IndicationTotal, No. (%)Diagnostic yield, No. (%)Additional biopsy tools, No. (%)ForcepsNeedle Mucosal/endobronchial 29 (53)20 (69)7 (24)1 (3) Transbronchial 19 (35)14 (74)7 (37)5 (26) Lymph node 12 (22)11 (92)3 (25)11 (92) Total 55a40 (73)15 (27)13 (24)aFive cases involved multiple biopsy types. Cryobiopsy. Five cases involved multiple biopsy types. Table 7Cryorecanalization.IndicationTotal, No. (%)Cryorecanalization success, No. (%)Additional tools, No. (%)YesPartialNoNeedleForcepsBalloonCauteryAPC Granulation tissue 43 (36)25 (58)17 (40)1 (2)0 (0)12 (28)8 (19)2 (5)0 (0) Tumor 20 (17)12 (60)6 (30)2 (10)0 (0)5 (25)0 (0)1 (5)1 (5) Stenosisa 51 (43)30 (59)17 (33)0 (0)8 (16)5 (10)30 (59)2 (4)0 (0) Othera 8 (7)5 (63)2 (25)0 (0)0 (0)2 (25)0 (0)0 (0)0 (0) Total 119b70 (59)41 (34)8 (7)8 (7)24 (20)35 (29)4 (3)1 (1)Abbreviation: APC, Argon plasma coagulation.aSuccess not reported in 4 cases of recanalization for stenosis and 1 for recanalization of other.bThree cases involved multiple recanalization indications (granulation tissue and stenosis). Cryorecanalization. Abbreviation: APC, Argon plasma coagulation. Success not reported in 4 cases of recanalization for stenosis and 1 for recanalization of other. Three cases involved multiple recanalization indications (granulation tissue and stenosis). Trends in cryotherapy and cryobiopsy use over time in the pediatric airway via flexible bronchoscopy. The left mainstem bronchus and trachea were the most common sites for cryotherapy and cryobiopsy across all applications, followed by the left lower lobe and right mainstem bronchus (Figure 2). Location of cryotherapy and cryobiopsy procedures performed within the pediatric airway. Solid black circles represent transbronchial nodal biopsies. Many procedures included multiple locations. Created in BioRender. https://BioRender.com/d7krdzp. Outcomes and complications In analyzing outcomes for cryoextraction, 151 (95%) of the 159 procedures were at least partially successful, with 44 (28%) using additional tools such as forceps or a basket (Table 5). There was a total of 10 extractions with 2 indications (8 with mucus and blood clot, 1 with mucus and casts, and 1 with blood clot and casts). Of the 55 cryobiopsy procedures, the diagnostic yield was 73% (Table 6). The most common reported diagnosis from the cryobiopsy was a solid tumor (n = 10, 18%), which included inflammatory myofibroblastic tumors, carcinoid tumors, Signet ring cell adenocarcinoma, and a peripheral nerve sheath tumor. Infection was the next most common biopsy result (n = 9, 16%), followed by lymphoma (n = 4, 7%). Other reported biopsy results included granulomas, vasculitis, posttransplant lymphoproliferative disorder, sarcoidosis, interstitial lung disease, reactive lymphadenopathy, and normal lung. A total of 111 (93%) cryorecanalization procedures were partially or completely successful (Table 7). When cryoablation (cryodevitalization) was used as part of the cryorecanalization procedure, the median freeze time was 30 seconds with a median of 5 freeze/thaw cycles completed. Bleeding was the most prevalent complication, occurring in 35% of cases, with 42 (38%) classified as grade 1 and 64 (58%) as grade 2. There were 5 grade 3 bleeding complications but no reported grade 4 events (Table 7). When broken down by procedure indication, bleeding occurred in 28% of cryoextraction cases, 71% of cryobiopsy cases, and 34% of cryorecanalization cases (Table 8). Most of the bleeding events related to cryoextraction (81%) were related to cryoextraction of blood clots (Table 9). For the 34 cases of cryotherapy performed in patients on ECMO, 8 (24%) had bleeding, with 6 reported to be grade 1 and 1 each reported to be grades 2 and 3. Table 8Complications.CharacteristicNo. (%) None 200 (63) Bleedinga 111 (35) Grade 1 42 (38) Grade 2 64 (58) Grade 3 5 (5) Grade 4 0 (0) Aborted procedure 2 (0.6) Symptomatic edema 1 (0.3) Airway perforation/pneumothorax 0 (0) Arrhythmia 0 (0) Hemodynamic instability 1 (0.3) Hypoxemiab 1 (0.3) Hypercapniab 1 (0.3) Laryngospasmb 1 (0.3) Technical difficulty 0 (0) Unplanned admission or escalation of care 3 (0.9) Death 0 (0) Other 1 (0.3)aBased on Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18bDefined as a complication if it led to a change in patient status, a change in airway, or early termination of the procedure. Complications. Based on Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18 Defined as a complication if it led to a change in patient status, a change in airway, or early termination of the procedure. Table 9Bleeding based on procedure type.Bleeding grade,a No. (%)IndicationNoneGrade 1Grade 2Grade 3Grade 4 Cryoextraction 115 (72)18 (11)22 (14)4 (3)0 (0) Foreign body 16 (89)1 (6)1 (6)0 (0)0 (0) Mucus plugs 21 (84)2 (8)2 (8)0 (0)0 (0) Blood clot 54 (60)15 (17)17 (19)4 (4)0 (0) Casts 30 (83)2 (6)4 (11)0 (0)0 (0) Cryobiopsy 16 (29)18 (33)21 (38)0 (0)0 (0) Mucosal/endobronchial 7 (24)6 (21)16 (55)0 (0)0 (0) Transbronchial 4 (21)9 (47)6 (32)0 (0)0 (0) Lymph node 7 (58)3 (25)2 (17)0 (0)0 (0) Cryorecanalization 79 (66)10 (8)29 (24)1 (1)0 (0) Granulation tissue 26 (60)4 (9)13 (30)0 (0)0 (0) Tumor 8 (40)5 (25)6 (30)1 (5)0 (0) Stenosis 41 (80)0 (0)10 (20)0 (0)0 (0) Other 6 (75)1 (13)1 (13)0 (0)0 (0)aBased on Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18 Bleeding based on procedure type. Based on Nashville Working Group Standardized Definitions of Bleeding After Transbronchial Lung Biopsy.18 Other complications were infrequent and included 2 (0.6%) aborted procedures (for a nonfunctional probe and another for the inability to extract a foreign body). One patient experienced symptomatic airway edema that necessitated steroids after prolonged cryoextraction of casts. Three patients (0.9%) required a higher level of care or an unplanned hospital admission after the procedure (Table 7). There was no pneumothorax reported. Discussion The use of cryotherapy and cryobiopsy via flexible bronchoscopy has increased over time and is now the most frequently reported advanced bronchoscopy skill in pediatric pulmonology.21 This growth is linked to the introduction of the 1.1-mm cryoprobe, which we found was the most used cryoprobe in pediatrics. This marks a shift from a few years ago, when the 1.9-mm probe was predominantly reported in pediatric cases.15 Over one-third of procedures were done with a working channel that would not have accommodated a probe larger than the 1.1-mm probe. Unsurprisingly, the most common indication was cryoextraction. In addition to diagnostic evaluations, including the bronchoalveolar lavage, therapeutic clearance of the airway is a fundamental aspect of flexible bronchoscopy. The application of cryotherapy for the removal of foreign bodies, mucus, blood clots, and casts is a logical entry point for the use of cryotherapy in pediatrics. Our data demonstrate that cryoextraction is helpful in most cases, although success may not be as high as that published in prior pediatric and adult literature.22,23 This difference is likely due to institutional practice and case selection bias as half of our patients (n = 9, 50%) had foreign bodies in the left mainstem bronchus or more distal left airways and none in the upper airway or trachea. Cryoextraction was likely chosen in our study sample due to the more challenging location of the foreign bodies, leading to the lower success rate. As advanced diagnostic and therapeutic bronchoscopy techniques are integrated into pediatric care, alternative applications, such as cryobiopsy, are emerging. Initially, bleeding was a concern with cryobiopsies when using larger probe sizes, but more recent data using a 1.1-mm cryoprobe and an oversheath showed an acceptable safety profile with no severe bleeding.18,19 Additionally, while cryobiopsies may not increase diagnostic yield in adult lung cancer, they do improve yield for other conditions, such as lymphoma, benign disorders, and diffuse parenchymal lung diseases.11,24,25 Our findings, while not a direct comparison, are in line with these prior adult studies in terms of diagnostic yield, with no severe bleeding when used for cryobiopsy in children. Therefore, the 1.1-mm cryoprobe may be one of the most innovative tools recently developed for the diagnosis of lung pathology in pediatric patients. We found that bleeding was also the largest complication related to the use of cryotherapy and cryobiopsy. Most bleeding complications (96%) were classified as either grade 1 or 2 on the Nashville Grading Scale. The bleeding complication for patients on ECMO did not appear to differ from the overall cohort. More severe (grade 3) bleeding primarily occurred in patients who were undergoing blood clot cryoextraction. Only 1 patient in this study had grade 3 bleeding during tumor debulking. Other complications were rare and no pneumothorax was reported, although pneumothorax requiring chest tube drainage has been reported in other studies specifically examining pediatric lung cryobiopsy.11 Overall, this study reinforces the safety of this technology in the smaller pediatric airway when done by experienced physicians. Nevertheless, pulmonologists performing cryotherapy and cryobiopsies should be thoughtful in patient selection, approach, and preparation. They should be well trained in managing bleeding complications, including using bronchoscope wedging, medication administration (oxymetazoline, epinephrine, and tranexamic acid), and lung isolation techniques (bronchial blocker placement, single-lung intubation, and ventilation). In our study, 3 centers rely on 1 to 2 bronchoscopists for cryotherapy and cryobiopsy, while 2 centers have 3 to 5 bronchoscopists trained. Following recommendations from the European Respiratory Society and American Thoracic Society, interested bronchoscopists should have a high level of expertise and experience in bronchoscopy and then train on inanimate or animal models first, which can be found at various cryotherapy courses, followed by 5 to 10 supervised procedures before independent practice.2 This number will vary based on the types of cryotherapy or cryobiopsy procedures a provider wishes to offer at their institution. Limitations This study has several limitations, primarily its retrospective nature. This leads to challenges specifically when defining procedure success in cryorecanalization. Therefore, success was evaluated subjectively based on the documented procedure intent and details, short-term follow-up, and any subsequent bronchoscopic evaluation. Additionally, while we characterized the use of cryotherapy and cryobiopsy in pediatrics across multiple institutions and numerous cases, we did not directly compare it to alternative instruments, such forceps or suction. In most instances, however, it is likely the cryoprobe was chosen because other tools were inadequate for achieving the procedural goals. Our findings suggest that cryotherapy and cryobiopsy via flexible bronchoscopy represent a promising and increasingly used tool in pediatric pulmonology, particularly in cases where traditional instruments may be insufficient. While the safety profile appears favorable, the field would benefit from standardized training programs. Additionally, while success and diagnostic yield rates are encouraging, the field would benefit from prospective studies, including newer and more precise calculations of diagnostic yield when more data are available to review.26 As experience with this technology grows and more centers adopt it into practice, cryotherapy and cryobiopsy will become an integral part of the pediatric bronchoscopist’s toolset. Conclusion Cryotherapy and cryobiopsy via flexible bronchoscopy in the pediatric airway are a growing practice, with early studies showing good efficacy and favorable safety. The 1.1-mm cryoprobe has facilitated its broader application. Bleeding is the most common complication but was generally mild in specialized centers. Supplementary Material Contributor Information Alex J Katz, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States. Haley Haskett, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States. Kubra M Bozkanat, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Division of Pediatric Pulmonary, Asthma and Sleep Medicine, Stanford University School of Medicine, Palo Alto, CA, United States. Aoife Corcoran, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Lauren M C Grant, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States. Antoinette Wannes Daou, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Sin Tran, Department of Nursing and Clinical Care Services, Children’s Hospital of Philadelphia, Philadelphia, PA, United States. Esra Caylan, Division of Pediatric Pulmonology and Sleep Medicine, UT Southwestern Medical Center, Dallas, TX, United States. Alfin Vicencio, Division of Pediatric Pulmonology, Icahn School of Medicine at Mount Sinai, New York, NY, United States. Dan T Benscoter, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Cherie A Torres-Silva, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Sara M Zak, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Gregory Burg, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Lisa R Young, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Pelton Phinizy, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Shailendra Das, Division of Pulmonary Medicine, Baylor College of Medicine, Houston, TX, United States. Erik B Hysinger, Division of Pulmonary Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, United States; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Joseph Piccione, Email: PiccioneJ@chop.edu, Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, PA, United States; Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States. Author contributions J.P. takes responsibility for the paper as a whole. The manuscript was drafted by A.J.K. and all authors contributed substantially to its revision. Supplementary material Supplementary material is available at Annals of the American Thoracic Society online. Conflicts of interest Please see the ICMJE disclosure forms, which have been provided as supplementary material. Artificial intelligence disclaimer No artificial intelligence tools were used in writing this manuscript. References Associated Data Supplementary Materials